Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $30.83 million
- Outstanding Shares: 17,619,000
Average Prices:- 50 Day Moving Avg: $1.36
- 200 Day Moving Avg: $1.43
- 52 Week Range: $1.10 - $11.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.04
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.67 per share
- Price / Book: 1.02
Profitability:- EBIDTA: ($26,350,000.00)
- Return on Equity: -72.02%
- Return on Assets: -64.41%
Debt:- Current Ratio: 8.00%
- Quick Ratio: 8.00%
Misc:- Average Volume: 63,706 shs.
- Beta: 1.5
- Short Ratio: 2.01
Frequently Asked Questions for Proteon Therapeutics (NASDAQ:PRTO)
What is Proteon Therapeutics' stock symbol?
Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."
How were Proteon Therapeutics' earnings last quarter?
Proteon Therapeutics, Inc. (NASDAQ:PRTO) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.11. View Proteon Therapeutics' Earnings History.
When will Proteon Therapeutics make its next earnings announcement?
Where is Proteon Therapeutics' stock going? Where will Proteon Therapeutics' stock price be in 2017?
8 equities research analysts have issued 1 year price targets for Proteon Therapeutics' shares. Their forecasts range from $2.00 to $21.00. On average, they anticipate Proteon Therapeutics' stock price to reach $9.00 in the next year. View Analyst Ratings for Proteon Therapeutics.
What are analysts saying about Proteon Therapeutics stock?
Here are some recent quotes from research analysts about Proteon Therapeutics stock:
- 1. According to Zacks Investment Research, "Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. " (7/13/2017)
- 2. Robert W. Baird analysts commented, "Focus of the call was on changes to the ongoing PATENCY-2 study of vonapanitase, following disappointing results from the first identically designed PATENCY-1 study announced late last year. Key changes, supported by the FDA, include a reordering of the primary endpoint (now a co-primary) and expanding the study (300 to 500 patients), with data now expected in 4Q18 (2Q18 previously). While we are encouraged by a potential path forward for vonapanitase, lack of meaningful updates near-term keeps us on the sidelines." (3/16/2017)
- 3. Maxim Group analysts commented, "Proteon reported YE16 with a net loss of $28.5M and ended the year with $41M in cash on the balance sheet." (3/16/2017)
Who are some of Proteon Therapeutics' key competitors?
Some companies that are related to Proteon Therapeutics include Egalet Corporation (EGLT), TRACON Pharmaceuticals (TCON), Endocyte (ECYT), vTv Therapeutics (VTVT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), Leap Therapeutics (LPTX), Xenon Pharmaceuticals (XENE), OptiBiotix Health PLC (OPTI), Capricor Therapeutics (CAPR), pSivida Corp. (PSDV), Proteostasis Therapeutics (PTI), Avacta Group Plc (AVCT), Actinium Pharmaceuticals (ATNM), Microbot Medical (MBOT), Nivalis Therapeutics (ALPN), Inotek Pharmaceuticals Corporation (ITEK) and Ampio Pharmaceuticals (AMPE).
Who are Proteon Therapeutics' key executives?
Proteon Therapeutics' management team includes the folowing people:
- Paul J. Hastings, Chairman of the Board
- Timothy P. Noyes, President, CEO, Director
- George A. Eldridge, Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary, IR Contact Officer
- E. Scott Toner, Senior Vice President - Marketing
- Steven K. Burke M.D., Senior Vice President, Chief Medical Officer
- Matthew Paul Kowalsky, Vice President, Legal and Secretary
- Daniel P. Gottlieb, Vice President - Corporate Development
- Jonathan Leff, Director
- Hubert Birner Ph.D., Independent Director
- Garen G. Bohlin, Independent Director
Who owns Proteon Therapeutics stock?
Proteon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
FLYNN JAMES E
(9.99%),
FLYNN JAMES E
(9.99%),
TVM LIFE SCIENCE VENTURES VI LP
(11.60%), RA Capital Management LLC (7.59%),
FLYNN JAMES E
(6.97%) and Pharmstandard International S.A. (6.61%). Company insiders that own Proteon Therapeutics stock include George Arthur Eldridge and Timothy P Noyes. View Institutional Ownership Trends for Proteon Therapeutics.
Who sold Proteon Therapeutics stock? Who is selling Proteon Therapeutics stock?
Who bought Proteon Therapeutics stock? Who is buying Proteon Therapeutics stock?
How do I buy Proteon Therapeutics stock?
Shares of Proteon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteon Therapeutics' stock price today?
One share of Proteon Therapeutics stock can currently be purchased for approximately $1.70.
MarketBeat Community Rating for Proteon Therapeutics (NASDAQ PRTO)MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Proteon Therapeutics (NASDAQ:PRTO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.13) |
| Consensus Price Target: | $9.00 (429.41% upside) |
Analysts' Ratings History for Proteon Therapeutics (NASDAQ:PRTO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Market Perform | | Low |  |
| 8/9/2017 | HC Wainwright | Set Price Target | Hold | $2.00 | Low | |
| 8/8/2017 | Cowen and Company | Reiterated Rating | Hold | | Low | |
| 5/4/2017 | Maxim Group | Set Price Target | Buy | $6.00 | High | |
| 3/16/2017 | Robert W. Baird | Reiterated Rating | Neutral | $3.00 | Low | |
| 12/14/2016 | Raymond James Financial, Inc. | Reiterated Rating | Strong-Buy -> Market Perform | | N/A | |
| 12/14/2016 | JMP Securities | Downgrade | Outperform -> Market Perform | | N/A | |
| 12/14/2016 | Stifel Nicolaus | Downgrade | Buy -> Hold | $19.00 -> $3.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Proteon Therapeutics (NASDAQ:PRTO)Earnings History by Quarter for Proteon Therapeutics (NASDAQ PRTO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.39) | | | | | N/A | |
| 8/7/2017 | Q2 2017 | ($0.44) | ($0.33) | | | View | N/A | |
| 5/10/2017 | Q1 2017 | ($0.43) | ($0.39) | | | View | N/A | |
| 11/7/2016 | Q3 2016 | ($0.46) | ($0.43) | | | View | N/A | |
| 5/9/2016 | Q1 | ($0.41) | ($0.40) | | | View | N/A | |
| 3/14/2016 | | ($0.34) | ($0.39) | | | View | N/A | |
| 11/12/2015 | Q315 | ($0.33) | ($0.33) | | | View | N/A | |
| 8/13/2015 | Q215 | ($0.30) | ($0.31) | | | View | N/A | |
| 5/13/2015 | | ($0.24) | ($0.28) | | | View | N/A | |
| 3/20/2015 | | ($0.26) | ($0.24) | | | View | N/A | |
| 11/25/2014 | | ($0.31) | ($31.03) | | $2.95 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Proteon Therapeutics (NASDAQ:PRTO)2017 EPS Consensus Estimate: ($1.56)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.44) | ($0.44) | ($0.44) |
| Q2 2017 | 1 | ($0.44) | ($0.44) | ($0.44) |
| Q3 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q4 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
(Data provided by Zacks Investment Research)
Dividend History for Proteon Therapeutics (NASDAQ:PRTO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Proteon Therapeutics (NASDAQ:PRTO)Insider Ownership Percentage: 36.30%
Institutional Ownership Percentage: 47.16%
Insider Trades by Quarter for Proteon Therapeutics (NASDAQ:PRTO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/6/2016 | George Arthur Eldridge | CFO | Buy | 4,000 | $5.78 | $23,120.00 | |
| 12/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $14.97 | $74,850.00 | |
| 11/2/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.50 | $67,500.00 | |
| 10/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.33 | $66,650.00 | |
| 9/8/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.55 | $67,750.00 | |
| 7/7/2015 | Daniel Philip Gottlieb | VP | Sell | 1,965 | $16.86 | $33,129.90 | |
| 10/27/2014 | James E Flynn | Insider | Buy | 691,713 | $10.00 | $6,917,130.00 | |
| 10/27/2014 | Skyline Venture Partners Quali | Major Shareholder | Sell | 56,038 | $10.00 | $560,380.00 | |
| 10/27/2014 | Timothy Haines | Director | Buy | 950,000 | $10.00 | $9,500,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Proteon Therapeutics (NASDAQ:PRTO)
Latest Headlines for Proteon Therapeutics (NASDAQ:PRTO)
| Source: |
|
| Date | Headline |
|---|
 | Head-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO)
www.americanbankingnews.com - September 22 at 6:06 AM |
 | Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017
finance.yahoo.com - September 6 at 7:28 AM |
| Proteon Therapeutics, Inc. (PRTO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 5 at 9:00 PM |
| -$0.39 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - August 22 at 4:14 PM |
| Proteon Therapeutics, Inc. (PRTO) Forecasted to Earn Q3 2017 Earnings of ($0.34) Per Share
www.americanbankingnews.com - August 18 at 6:26 AM |
| Proteon Therapeutics' (PRTO) "Market Perform" Rating Reiterated at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 16 at 2:41 PM |
| Proteon Therapeutics, Inc. (PRTO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 9:06 PM |
| Proteon Therapeutics' (NASDAQ:PRTO) "Hold" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - August 9 at 12:38 AM |
| Proteon Therapeutics, Inc. (NASDAQ:PRTO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS
www.americanbankingnews.com - August 8 at 11:14 AM |
| Proteon Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 6:22 AM |
| Proteon Therapeutics, Inc. (NASDAQ:PRTO) Expected to Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - August 4 at 12:28 PM |
| Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
finance.yahoo.com - August 3 at 7:06 AM |
| Proteon Therapeutics, Inc. (NASDAQ:PRTO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 17 at 8:28 PM |
| Proteon Therapeutics, Inc. (PRTO) Expected to Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - July 13 at 8:29 AM |
| Proteon Therapeutics Announces $22.0 Million Private Placement
finance.yahoo.com - June 23 at 9:16 AM |
| Proteon Therapeutics, Inc. (PRTO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - June 20 at 8:52 PM |
| Zacks: Analysts Anticipate Proteon Therapeutics, Inc. (PRTO) to Announce -$0.46 EPS
www.americanbankingnews.com - June 19 at 7:54 AM |
| Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
finance.yahoo.com - June 16 at 9:03 AM |
| Proteon Therapeutics Inc (PRTO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 26 at 9:04 PM |
| Proteon Therapeutics Inc (PRTO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 17 at 7:50 AM |
| Proteon Therapeutics Inc (PRTO) Announces Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 11 at 10:52 PM |
 | Proteon Therapeutics Announces First Quarter 2017 Financial Results
globenewswire.com - May 10 at 7:33 PM |
 | Pre-Open Stock Movers 05/10: (PRTO) (NVDA) (INCR) Higher; (YELP) (VSI) (FOSL) Lower (more...)
www.streetinsider.com - May 10 at 11:29 AM |
 | Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
www.nasdaq.com - May 10 at 11:29 AM |
 | Proteon Therapeutics reports 1Q loss
marketbeat.com - May 10 at 8:13 AM |
| Maxim Group Analysts Give Proteon Therapeutics Inc (PRTO) a $6.00 Price Target
www.americanbankingnews.com - May 7 at 7:34 AM |
| Proteon Therapeutics (PRTO) Earning Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - May 3 at 1:11 AM |
| Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
finance.yahoo.com - May 2 at 5:09 PM |
| Proteon Therapeutics Inc (PRTO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 1 at 10:42 PM |
| Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th
finance.yahoo.com - May 1 at 11:11 AM |
| Brokerages Expect Proteon Therapeutics Inc (PRTO) to Announce -$0.45 EPS
www.americanbankingnews.com - May 1 at 11:05 AM |
| Proteon Therapeutics (PRTO) Receiving Somewhat Negative Media Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 3:08 PM |
| Proteon Therapeutics (PRTO) Given Media Sentiment Score of 0.12
www.americanbankingnews.com - April 23 at 8:09 PM |
| Proteon Therapeutics (PRTO) Given News Sentiment Score of 0.06
www.americanbankingnews.com - April 21 at 12:33 AM |
| Proteon Therapeutics (PRTO) Earning Somewhat Negative Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 2:13 PM |
| -$0.45 EPS Expected for Proteon Therapeutics Inc (PRTO) This Quarter
www.americanbankingnews.com - April 8 at 12:24 AM |
| Proteon Therapeutics Inc (PRTO) Short Interest Update
www.americanbankingnews.com - April 7 at 5:31 PM |
| Proteon Therapeutics Inc (PRTO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 4 at 6:09 PM |
| Proteon Therapeutics Inc (PRTO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 27 at 10:08 AM |
| Proteon Therapeutics Inc (PRTO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 25 at 2:39 PM |
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible ... - Business Wire (press release)
www.businesswire.com - March 24 at 8:16 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc.
finance.yahoo.com - March 23 at 7:47 PM |
| PROTEON THERAPEUTICS INC Financials
finance.yahoo.com - March 22 at 7:19 PM |
| Maxim Group Reiterates Buy Rating for Proteon Therapeutics Inc (PRTO)
www.americanbankingnews.com - March 22 at 8:13 AM |
| PROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 22 at 7:30 AM |
 | Proteon Therapeutics' (PRTO) Management Discuses Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial ... - Seeking Alpha
seekingalpha.com - March 17 at 7:28 PM |
| Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd
finance.yahoo.com - March 17 at 7:28 PM |
 | Proteon CEO: New trial could be a path to market
www.bizjournals.com - March 17 at 7:28 PM |
| HC Wainwright Lowers Proteon Therapeutics Inc (PRTO) to Neutral
www.americanbankingnews.com - March 17 at 11:19 AM |
| PROTEON THERAPEUTICS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 16 at 8:07 PM |
Proteon Therapeutics (PRTO) Chart for Tuesday, September, 26, 2017
